Skip to search formSkip to main contentSkip to account menu

CD101 gene

Known as: IMMUNOGLOBULIN SUPERFAMILY, MEMBER 2, CD101, CD101 molecule 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2018
Highly Cited
2018
Pharmacodynamic Evaluation of Rezafungin (CD101) against Candida auris in the Neutropenic Mouse Invasive Candidiasis Model
Rezafungin (CD101) is a novel echinocandin under development for once-weekly intravenous (i.v.) dosing. We evaluated the… 
Highly Cited
2017
Highly Cited
2017
Unraveling Drug Penetration of Echinocandin Antifungals at the Site of Infection in an Intra-abdominal Abscess Model
ABSTRACT Intra-abdominal candidiasis (IAC) is a prominent invasive fungal infection associated with high mortality. Prompt… 
Highly Cited
2017
Highly Cited
2017
Activity of CD101, a long-acting echinocandin, against clinical isolates of Candida auris.
2017
2017
Activity of a Long-Acting Echinocandin (CD101) and Seven Comparator Antifungal Agents Tested against a Global Collection of Contemporary Invasive Fungal Isolates in the SENTRY 2014 Antifungal…
ABSTRACT The activity of CD101 and comparator antifungal agents against 606 invasive fungal isolates collected worldwide during… 
Highly Cited
2016
Highly Cited
2016
Preclinical Evaluation of the Stability, Safety, and Efficacy of CD101, a Novel Echinocandin
ABSTRACT Fungal infections pose a significant public health burden with high morbidity and mortality. CD101 is a novel… 
Highly Cited
2016
Highly Cited
2016
Safety and Pharmacokinetics of CD101 IV, a Novel Echinocandin, in Healthy Adults
ABSTRACT CD101 IV is a novel echinocandin with distinctive pharmacokinetic properties that is being developed as a once-weekly… 
Highly Cited
2016
Highly Cited
2016
CD101, a novel echinocandin with exceptional stability properties and enhanced aqueous solubility
The echinocandins are an important class of antifungal agents. However, instability and, in some cases, lack of solubility have… 
Highly Cited
2016
Highly Cited
2016
Activity of a long-acting echinocandin, CD101, determined using CLSI and EUCAST reference methods, against Candida and Aspergillus spp., including echinocandin- and azole-resistant isolates
Objectives The objective of this study was to evaluate the in vitro activity of CD101, a novel echinocandin with a long serum… 
2016
2016
Characterization of In Vitro Resistance Development to the Novel Echinocandin CD101 in Candida Species
ABSTRACT CD101 is a novel echinocandin with a long half-life undergoing clinical development for treatment of candidemia/invasive… 
Highly Cited
2016
Highly Cited
2016
CD101: a novel long‐acting echinocandin
CD101 is a novel echinocandin drug being developed to treat severe fungal infections including invasive candidiasis. We have… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)